aTyr Pharma (ATYR) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Seres Therapeutics is the larger company by market cap ($27.2 million vs $24.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATYR | MCRB |
|---|---|---|
| Share price | $0.2462 | $2.71 |
| Market cap | $24.15M | $27.22M |
| 1-day change | -3.56% | +3.04% |
| YTD return | -68.56% | — |
| 1-year return | -74.17% | — |
| 5-year return | -97.17% | — |
| EPS (TTM) | $-0.59 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.11 | $29.98 |
| 52-week low | $0.246 | $2.42 |
| Distance from 52-week high | -77.82% | -90.96% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1061.66% | +527.31% |
| Average volume | 3.23M | 72.26K |
| Shares outstanding | 98.09M | 10.04M |
| Employees | 58 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
ATYR vs MCRB FAQ
Which is bigger, aTyr Pharma or Seres Therapeutics?
Seres Therapeutics (MCRB) is larger, with a market capitalization of $27.22M compared with $24.15M for aTyr Pharma (ATYR).
Are aTyr Pharma and Seres Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for aTyr Pharma and Biotechnology: Pharmaceutical Preparations for Seres Therapeutics.